3Q Financial Reports

BMS

3Q Revenues: $4.2 billion (-13%)

3Q Earnings: $338 million (-65%)

YTD revenues: $13.7 billion (-3%)

YTD Earnings: $1.7 billion (-31%)

Comments: Results for the quarter and YTD were negatively impacted by the launch of generic clopidogrel bisulfate (Plavix) and loss of exclusivity of Pravachol. Plavix sales were down 36% and Pravachol sales were down 64% in the quarter. Erbitux, Abilify, Sustiva, Reyataz and Avapro/Avalide and sales of new products Orencia, Baraclude and Sprycel, all performed well in the quarter. In the quarter, BMS and Gilead Sciences submitted Atripla for regulatory approval in Canada. The company launched Baraclude for the treatment of chronic hepatitis B virus infection in Germany, France, the UK and Japan. Also, BMS and Sanofi-Aventis received approval from the FDA and the EMEA for an additional indication for Plavix.

Millennium Pharma

3Q Revenues: $104 million (-48%)

3Q Loss: $13.7 million (loss of $73.8 million 3Q2005)

YTD Revenues: $346.7 million (-20%)

YTD Loss: $52.2 million (loss of $154.3 million YTD2005)

Comments: Velcade sales in the quarter were $53.2 million, up 5%. Velcade was recently approved for marketing in Japan for relapsed or refractory multiple myeloma. The company’s sNDA for Velcade was recently granted priority review by the FDA for relapsed mantle cell lymphoma. R&D expenses were $70.4 million, down 9% in the quarter.